Modified apple polysaccharide prevents against tumorigenesis in a mouse model of colitis-associated colon cancer: role of galectin-3 and apoptosis in cancer prevention

Eur J Nutr. 2012 Feb;51(1):107-17. doi: 10.1007/s00394-011-0194-3. Epub 2011 Apr 24.

Abstract

Background: Colorectal cancer (CRC) is one of the most common and preventable cancers. Regular consumption of apples is conducive to reduction in CRC risk.

Aim of the study: To evaluate effects of modified apple polysaccharide (MAP) on tumorigenesis in a mouse model of colitis-associated colon cancer.

Methods: One hundred male ICR mice were administered with 1, 2-dimethyl-hydrazine (DMH) and dextran sodium sulfate (DSS). Forty mice were given no further treatment, the rest were fed basal diet blended with three different doses of MAP; 2.5, 5, and 10% (20 mice in each group).

Results: MAP significantly protected ICR mice against DMH/DSS-induced tumorigenesis. The incidence of tumor development was 90% (18/20) in the mice treated with DMH/DSS, but that was reduced to 25% (5/20), 15% (3/20), and 5% (1/20), respectively, in the mice treated with basal diets plus 2.5, 5, and 10% of MAP. Study of apoptosis of colonic epithelial cells revealed that MAP moderately increased apoptosis, suggesting that the anti-tumor potency of MAP was probably attributed to its ability to induce apoptosis. Western blot analysis demonstrated that carbohydrate-binding protein galectin-3 changed in both the nucleus and the cytoplasm during the process from colitis to colon cancer in the model. And MAP could inhibit the binding of galectin-3 to its ligand: this is, at least in part, the possible mechanism of MAP by enhancing apoptosis and preventing tumorigenesis.

Conclusions: These data suggest that MAP has a potential role in clinical prevention and treatment for colon cancer.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticarcinogenic Agents / chemistry
  • Anticarcinogenic Agents / isolation & purification
  • Anticarcinogenic Agents / metabolism
  • Anticarcinogenic Agents / therapeutic use*
  • Apoptosis*
  • Cell Line, Tumor
  • Cell Nucleus / metabolism
  • Cell Transformation, Neoplastic
  • Colitis / physiopathology*
  • Colonic Neoplasms / etiology
  • Colonic Neoplasms / metabolism
  • Colonic Neoplasms / pathology
  • Colonic Neoplasms / prevention & control*
  • Cytoplasm / metabolism
  • Dietary Supplements / analysis
  • Disease Models, Animal
  • Enterocytes / immunology
  • Enterocytes / metabolism
  • Enterocytes / pathology
  • Fruit / chemistry
  • Galectin 3 / blood
  • Galectin 3 / metabolism*
  • Humans
  • Male
  • Malus / chemistry*
  • Mice
  • Mice, Inbred ICR
  • Neoplasm Proteins / metabolism
  • Polysaccharides / chemistry
  • Polysaccharides / isolation & purification
  • Polysaccharides / metabolism
  • Polysaccharides / therapeutic use*
  • Random Allocation

Substances

  • Anticarcinogenic Agents
  • Galectin 3
  • Neoplasm Proteins
  • Polysaccharides